~~<i id='FE20C10CD7'><strike id='FE20C10CD7'><tt id='FE20C10CD7'><pre id='FE20C10CD7'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

focus

author：explore 2025-10-01 17:34:50 - browse：4

JOHNSON & JOHNSON HEADQUARTERS — Daniel Hulshizer/AP

Eight months into his tenure, Johnson & Johnson’s R&D chief is putting a big emphasis on medicines for cancer, treatment-resistant depression, and autoimmune disease.

To sharpen that focus, R&D chief John Reed told STAT that the company is de-emphasizing two areas that have been mainstays for the drug and medical device giant: infectious disease and vaccines, as well as medicines targeting kidney disease and rare eye conditions.

The disclosures were made in an interview ahead of an investor meeting Reed is leading Tuesday aimed at generating excitement about the company’s research and development efforts.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The high cost of giving birth even with insurance
Next article： Fentanyl is making it harder to start addiction treatment

knowledge

focus

hotspot

focus

explore

focus

NIHDirectorMonicaBertagnolliKevinDietsch/GettyImagesWASHINGTON—PresidentBidenhaspromisedtorequirefai

WSS

Medicare Advantage today, explained in one chart

Readout LOUD podcast: Biotech layoffs, stock slump, 2024 preview

Cue Health, Covid

New brain studies show LSD's effects on the brain in full color

Listen: A conversation with researcher Kevin Esvelt on biosecurity

Think you might have Covid

focus

focus

knowledge

Supreme Court strikes down use of affirmative action

Elizabeth Holmes banned from government health programs

Walensky prepares to leave CDC — and Congress — behind

Dewpoint Therapeutics lays off staff after losing partnerships

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Biotech venture capitalists face new demands from investors

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

EU regulator recommends expanding Mounjaro approval to obesity

Supreme Court strikes down use of affirmative action

Gilead’s Trodelvy fails in lung cancer, raises questions on ADCs

focus

H5N1 bird flu outbreak: Second human case reported, in Michigan

Readout LOUD podcast: Biotech layoffs, stock slump, 2024 preview

Independent physicians launch a new lobbying group

Copay coupons to count toward deductibles, after Biden court move

Why doctors need education on FDA device approval process

UnitedHealth argues against case alleging wrongful AI care denials

hotspot

focus

explore

focus